STOCK TITAN

[6-K] Cellectis S.A. American Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

Date of Report: June 26, 2025

Commission File Number: 001-36891

Cellectis S.A.
(Exact Name of registrant as specified in its charter)

8, rue de la Croix Jarry
75013 Paris, France
+33 1 81 69 16 00

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

 

 


EXHIBIT INDEX

 

Exhibit Title
   
99.1 Press Release, dated June 26, 2025


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

      Cellectis S.A.    
  (Registrant)
   
  
Date: June 26, 2025     /s/ André Choulika    
  André Choulika
  Chief Executive Officer
  
Cellectis

NASDAQ:CLLS

CLLS Rankings

CLLS Latest News

CLLS Latest SEC Filings

CLLS Stock Data

144.47M
69.50M
3.87%
20.71%
0.24%
Biotechnology
Healthcare
Link
France
Paris